Every 10-Q that Immunitybio Inc (IBRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IBRX filings page.
ImmunityBio (IBRX) filed its Q3 2025 report showing rapid revenue ramp but continued losses and liquidity pressure. Total revenue reached $32.1 million for the quarter, up from $6.1 million a year ago, driven by U.S. commercialization of ANKTIVA. For the nine months, revenue was $75.0 million versus $7.2 million in 2024.
The company reported a Q3 net loss of $67.3 million and a loss from operations of $55.6 million. Year-to-date operating cash outflows were $234.6 million. Cash and cash equivalents were $60.2 million and marketable securities were $197.6 million as of September 30, 2025. Accounts receivable increased to $32.0 million, reflecting growing product sales.
Total liabilities were $1.04 billion, including a related-party convertible note at fair value of $500.8 million, a revenue interest liability of $316.1 million, and warrant liabilities of $115.2 million. The company raised $346.8 million net through equity offerings year-to-date, including “at-the-market” sales and other equity issuances. Shares outstanding were 984,965,179 as of October 30, 2025.
Management disclosed substantial doubt about continuing as a going concern without additional funding, noting reliance on existing cash, product sales, future equity offerings, and potential affiliated loans. In July 2025, ANKTIVA received UK marketing authorization, the first approval outside the U.S.
ImmunityBio, Inc. (IBRX) 10-Q — Quarter ended June 30, 2025: Condensed consolidated assets totaled $402,076 as of June 30, 2025, including $137,658 cash and cash equivalents, $16,000 marketable securities and $22,126 accounts receivable. Total current assets were $208,132. Major non‑current assets include PP&E net $133,004 and goodwill/intangibles net $14,977. Total liabilities were $971,895, driven notably by a $492,084 related‑party convertible note payable and a $307,049 revenue interest liability; warrant liabilities were $66,957. Stockholders' deficit was $(570,749).
Operating results and cash flows: Product revenue increased to $26,421 for Q2 2025 (Q2 2024: $990) and $42,930 for six months 2025 (six months 2024: $990). Loss from operations was $(71,285) for Q2 and $(135,714) for six months; net loss was $(92,574) for Q2 and $(222,240) for six months. Net cash used in operating activities for the six months was $(165,651). The company discloses an accumulated deficit of $3.6 billion and states substantial doubt about going concern without additional funding, though management cites expected support from the Founder and other sources.